Eplontersen Gets Orphan Drug Status for Transthyretin-Mediated Amyloidosis
Eplontersen is a ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.
Neurologic Disorders
AAN Position Statement Addresses Consent Issues in Acute Stroke
Inability to fulfill elements of decisional capacity coupled with need for rapid treatment decisions complicates consent
Epstein-Barr Virus Suspected as Cause of Multiple Sclerosis
Risk for MS increased 32-fold following EBV infection, but not following infection with other viruses, including cytomegalovirus
FDA Extends Review Period for Gene Therapies for Beta-Thalassemia, Cerebral Adrenoleukodystrophy
The FDA extended the target dates for beti-cel and eli-cel to allow time to review additional clinical information for both applications.
MPR Weekly Dose Podcast Episode 103
This week news of a new treatment for insomnia; The FDA comment on magnesium hypertension claims; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycles in relation to COVID vaccines; And experts have their say on the best diets for 2022.
Oral Formulation of Edaravone Gets Priority Review for ALS
Oral edaravone was developed to have a similar clinical profile as the intravenous formulation Radicava.
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Generic Version of Cuvposa Now Available
Glycopyrrolate Oral Solution is supplied as 1mg/5mL in a 16oz bottle.
Fixed-Dose Combo Therapy for ALS Gets Priority Review
AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.
Dopamine Agonists, DRIs Similar for QoL in Parkinson Disease
No measurable difference in patient-rated quality of life seen for dopamine agonists versus dopamine reuptake inhibitors as adjuvant therapy
